• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Syst . Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity

tetano

Editor, Senior Moderator
Cell Syst


. 2022 Jul 8;S2405-4712(22)00276-9.
doi: 10.1016/j.cels.2022.06.006. Online ahead of print.
Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity


Anoop T Ambikan[SUP] 1 [/SUP], Hong Yang[SUP] 2 [/SUP], Shuba Krishnan[SUP] 1 [/SUP], Sara Svensson Akusjärvi[SUP] 1 [/SUP], Soham Gupta[SUP] 1 [/SUP], Magda Lourda[SUP] 3 [/SUP], Maike Sperk[SUP] 1 [/SUP], Muhammad Arif[SUP] 2 [/SUP], Cheng Zhang[SUP] 2 [/SUP], Hampus Nordqvist[SUP] 4 [/SUP], Sivasankaran Munusamy Ponnan[SUP] 5 [/SUP], Anders Sönnerborg[SUP] 6 [/SUP], Carl Johan Treutiger[SUP] 7 [/SUP], Liam O'Mahony[SUP] 8 [/SUP], Adil Mardinoglu[SUP] 9 [/SUP], Rui Benfeitas[SUP] 10 [/SUP], Ujjwal Neogi[SUP] 11 [/SUP]



Affiliations

Abstract

The clinical outcome and disease severity in coronavirus disease 2019 (COVID-19) are heterogeneous, and the progression or fatality of the disease cannot be explained by a single factor like age or comorbidities. In this study, we used system-wide network-based system biology analysis using whole blood RNA sequencing, immunophenotyping by flow cytometry, plasma metabolomics, and single-cell-type metabolomics of monocytes to identify the potential determinants of COVID-19 severity at personalized and group levels. Digital cell quantification and immunophenotyping of the mononuclear phagocytes indicated a substantial role in coordinating the immune cells that mediate COVID-19 severity. Stratum-specific and personalized genome-scale metabolic modeling indicated monocarboxylate transporter family genes (e.g., SLC16A6), nucleoside transporter genes (e.g., SLC29A1), and metabolites such as α-ketoglutarate, succinate, malate, and butyrate could play a crucial role in COVID-19 severity. Metabolic perturbations targeting the central metabolic pathway (TCA cycle) can be an alternate treatment strategy in severe COVID-19.

Keywords: COVID-19; personalized genome-scale metabolic model; similarity network fusion.
 
Back
Top Bottom